Carmine Pinto1, Carlo A Barone, Giampiero Girolomoni, Elvio G Russi, Marco C Merlano, Daris Ferrari, Evaristo Maiello. 1. *Medical Oncology Unit, Clinical Cancer Centre, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia †Medical Oncology Unit, Università Cattolica Sacro Cuore, Rome ‡Department of Medicine, Section of Dermatology, University of Verona, Verona §Radiotherapy Unit ∥Oncology Unit, Santa Croce and Carle Hospital, Cuneo ¶Oncology Unit, San Paolo Hospital, Milan #Oncology Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy.
Abstract
OBJECTIVES: Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.
OBJECTIVES:Cetuximab was shown in phase III clinical trials to improve chemotherapy efficacy in patients with advanced colorectal and head-neck cancer. Appropriate management of skin reactions associated with epidermal growth factor receptor inhibitor therapy is necessary to allow adequate drug compliance and to improve patient quality of life and outcomes. METHODS: The RAND/UCLA Appropriateness Method was used by a group of experts to produce new Italian recommendations on the management of skin reactions in this setting. Statements were generated on the basis of an updated systematic review of the literature and rated twice by a panel of 38 expert physicians. A meeting of the panel was held after the first rating session. RESULTS: Skin reactions included acneiformic rash, skin dryness (xerosis), pruritus, paronychia, hair abnormalities, mucositis, and increased growth of eyelashes or facial hair. Updates of the previous recommendations on the prevention and treatment of each type of reaction were proposed. CONCLUSIONS: This updated Expert Opinion focuses on how to assess and correctly grade skin reactions according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events and on how to manage these adverse events in clinical practice.
Authors: Sana D Karam; Krishna Reddy; Patrick J Blatchford; Tim Waxweiler; Alicia M DeLouize; Ayman Oweida; Hilary Somerset; Carrie Marshall; Christian Young; Kurtis D Davies; Madeleine Kane; Aik Choo Tan; Xiao Jing Wang; Antonio Jimeno; Dara L Aisner; Daniel W Bowles; David Raben Journal: Clin Cancer Res Date: 2018-07-03 Impact factor: 12.531
Authors: Mario E Lacouture; Milan Anadkat; Aminah Jatoi; Tamer Garawin; Chet Bohac; Edith Mitchell Journal: Clin Colorectal Cancer Date: 2017-12-13 Impact factor: 4.481
Authors: Sacha I Rothschild; Daniel Betticher; Reinhard Zenhäusern; Sandro Anchisi; Roger von Moos; Miklos Pless; Peter Moosmann; Razvan A Popescu; Antonello Calderoni; Marco Dressler; Daniel Rauch; Stefanie Pederiva; Regina Woelky; Claudia Papet; Vera Bühler; Markus Borner Journal: Cancer Chemother Pharmacol Date: 2019-08-23 Impact factor: 3.333
Authors: Michele De Tursi; Marinella Zilli; Consiglia Carella; Matteo Auriemma; Maria Nadia Lisco; Marta Di Nicola; Giuseppe Di Martino; Clara Natoli; Paolo Amerio Journal: Onco Targets Ther Date: 2017-06-16 Impact factor: 4.147